I
The startup specializes in the mass production of clinical-grade induced pluripotent stem cells (iPSCs) using a proprietary automation method that enhances differentiation propensity selection from multiple donors. This technology increases the availability of diverse iPSC lines for personalized medicine research while significantly lowering production costs.
Palo Alto, United States
Updated 2 months ago
Funding
$37.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup specializes in the mass production of clinical-grade induced pluripotent stem cells (iPSCs) using a proprietary automation method that enhances differentiation propensity selection from multiple donors. This technology increases the availability of diverse iPSC lines for personalized medicine research while significantly lowering production costs.